9/103 sources · 3 publishersUpdated Oct 14, 07:35 UTC
Galderma to acquire ZO Skin Health for $1.5 billion
Galderma Group AG announced it will buy ZO Skin Health Inc. from Blackstone and the Obagi family for $1.5 billion in cash. The transaction is slated to close in early 2027, subject to regulatory approvals. ZO Skin Health posted $330 million of net sales for the year ended June 2026. The acquisition is expected to be earnings‑per‑share neutral in the first year.
Why it matters
The deal expands Galderma’s presence in the U.S. physician‑dispensed skincare market, which could boost future revenue streams. Lazard, JP Morgan and Ropes & Gray note the transaction should be EPS‑neutral in its first year, limiting short‑term earnings impact.
Key facts
- 1Galderma will acquire ZO Skin Health for $1.5 billion in cash. seekingalpha.com
- 2The acquisition is expected to close in early 2027, subject to regulatory approvals. rttnews.com
- 3ZO Skin Health reported $330 million in net sales for the year ended June 2026. rttnews.com
- 4The transaction will be funded through cash and bank financing. rttnews.com
- 5Lazard, JP Morgan and Ropes & Gray advised on the deal. tradingview.com
- 6The acquisition is expected to be EPS‑neutral in the first year. tradingview.com
Summary written by AlphAI AI Desk from 3 of 3 sources. Not investment advice. Figures are as stated by the linked sources.